SORT1
ENSG00000134243
Target class
Membrane receptor
Chromosome
1
- Chemical probe available
- No
- Target name
- SORT1
- Gene name
- Sortilin 1
- Gene symbol
- SORT1
- Protein name
- Sortilin (100 kDa NT receptor) (Glycoprotein 95) (Gp95) (Neurotensin receptor 3) (NT3) (NTR3)
- Gp95
- NT3
- Gene biotype
- Protein coding
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 183.26
- Tissue specificity (Gini)
- 0.412
- Tissue specificity (tau)
- 0.767
- KEGG gene identifiers
- hsa:6272
- Reactome pathways
- R-HSA-432722
- Protein interaction confidence
- 0.847756
- Protein interaction partners
- 41
- End position
- 109397967
- Start position
- 109309568
- Chromosome
- 1
- Strand
- Reverse
- Golgi apparatus, Golgi stack membrane
- Single-pass type I membrane protein . Endosome membrane
- Single-pass type I membrane protein . Endoplasmic reticulum membrane
- Single-pass type I membrane protein . Nucleus membrane
- Single-pass type I membrane protein . Cell membrane
- Single-pass type I membrane protein
- Extracellular side. Lysosome membrane
- Single-pass type I membrane protein . Note=Localized to membranes of the endoplasmic reticulum, endosomes, Golgi stack, lysosomes and nucleus. A small fraction of the protein is also localized to the plasma membrane. May also be found in SLC2A4/GLUT4 storage vesicles (GSVs) in adipocytes. Localization to the plasma membrane in adipocytes may be enhanced by insulin.
- Cytosol
- Golgi apparatus
- Plasma membrane
- PubMed 16787399
- PubMed 18817523
- Tissue specificity (tau)
- 0.766949
- Expression inequality (Gini)
- 0.411554
Expression in transcripts per million
- Artery - Tibial
- 183.26
- Brain - Spinal cord (cervical c-1)
- 180.68
- Artery - Coronary
- 172.11
- Artery - Aorta
- 165.92
- Brain - Frontal Cortex (BA9)
- 76.47
Expression in transcripts per million
- Artery - Tibial183.26
- Brain - Spinal cord (cervical c-1)180.68
- Artery - Coronary172.11
- Artery - Aorta165.92
- Brain - Frontal Cortex (BA9)76.47
- Nerve - Tibial74.63
- Brain - Hippocampus71.44
- Lung65.4
- Testis64.5
- Esophagus - Muscularis63.42
- Brain - Cortex61.01
- Muscle - Skeletal57.18
- Brain - Substantia nigra56.23
- Adipose - Subcutaneous56.21
- Esophagus - Gastroesophageal Junction52.7
- Thyroid50.18
- Brain - Caudate (basal ganglia)47.02
- Brain - Putamen (basal ganglia)45.33
- Brain - Anterior cingulate cortex (BA24)43.05
- Esophagus - Mucosa42.7
- Brain - Hypothalamus35.8
- Brain - Nucleus accumbens (basal ganglia)35.71
- Breast - Mammary Tissue35.16
- Uterus35.02
- Brain - Amygdala34.87
And 29 more, listed on the interactive page.
- GO:0006893
- GO:0006895
- GO:0006897
- GO:0008333
- GO:0014902
- GO:0016050
- GO:0032509
- GO:0032868
- GO:0048227
- GO:0090160
- GO:0005764
- GO:0005769
- GO:0005794
- GO:0005829
- GO:0005886
- GO:0005905
- GO:0009986
- GO:0010008
- GO:0030136
- GO:0031410
- GO:0048471
- GO:0005515
- GO:0019899
- GO:0038024
- GO:0048406
- GO:1905394
Related records
Trials (12)
- A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
- A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
- A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
- A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
- Continuation Study for Latozinemab
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
- Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
- Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
- Open-label Extension Study in Participants With Early Alzheimer's Disease
- Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
Drugs (2)
- Latozinemab
- Nivisnebart